Moderna to present late-breaking Phase 3 melanoma data for intisneran autogene at ESMO 2026

Moderna is scheduled to present late-breaking Phase 3 data for its intisneran autogene therapy in melanoma at the ESMO Congress on Oct. 24, 2026. The company will also present earlier-stage updates for the therapy in pancreatic cancer and early-stage NSCLC. The intisneran autogene is an individualized mRNA neoantigen therapy developed with Merck.